中超控股(002471.SZ):江蘇精鑄取得1項發明專利證書
格隆匯3月7日丨中超控股(002471.SZ)公佈,近日,公司控股孫公司江蘇精鑄收到中華人民共和國國家知識產權局頒發的《發明專利證書》,發明名稱為一種大型複雜薄壁高温合金鑄件疏鬆缺陷定量預測方法。
上述發明採用基於大型複雜薄壁高温合金鑄件結構分析、有限元計算和本體解剖,結合BP神經網絡定量預測疏鬆缺陷,有效規避了疏鬆形成機制複雜,現有理論模型無法實現準確預測,也難以構建新型數學模型對疏鬆缺陷進行定量預測的問題,採用構建BP神經網絡實現了大型複雜薄壁高温合金鑄件疏鬆缺陷定量預測。也有利於獲得疏鬆缺陷敏感工藝參數,為工藝優化抑制疏鬆提供指導方向,此外,該預測方法也可推廣到其他合金疏鬆缺陷定量預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.